IPO registrations (S-1, F-1) · Registrants
REGENXBIO Inc.
- SEC CIK
- 1590877 · filings on EDGAR ↗
- Former names
- ReGenX Biosciences, LLC (2013–2013)
- Registration
- Form S-1, first filed 2015-08-17, last 2015-09-16; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2015-09-17; declared effective 2015-09-16
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Business address
- 9804 MEDICAL CENTER DRIVE, Rockville, MD 20850
- EIN
- 47-1851754
- Ticker
- RGNX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- REGENXBIO Inc. on the corporate pages
Offering terms
- Final price
- $22.00 per share (424B4 filed 2015-09-17, an initial public offering)
- Shares sold
- 6,300,000
- Gross proceeds
- $138,600,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RGNX
- Lead underwriters
- Morgan Stanley (2,583,000 shares); Merrill Lynch (2,205,000 shares)
- Syndicate
- BofA Securities; Piper Sandler (1,008,000); Chardan (504,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: REGENXBIO INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: REGENXBIO Inc. Fuzzy (name and state)
- Business registration: REGENXBIO INC. Fuzzy (name and state)
- Business registration: REGENXBIO INC. Fuzzy (name and state)
- Business registration: REGENXBIO INC. Fuzzy (name and state)
- Business registration: REGENXBIO INC. Fuzzy (name and state)
- Form 5500 plan sponsor: REGENXBIO INC. EXACT (EIN (EXACT))
- Form D issuer: REGENXBIO Inc. EXACT (CIK (EXACT))
- Lobbying client: REGENXBIO Fuzzy (name and state)
- Lobbying client: REGENXBIO Fuzzy (name and state)
- Lobbying client: REGENXBIO Fuzzy (name and state)
- Lobbying client: REGENXBIO INC. Fuzzy (name and state)
- Lobbying client: REGENXBIO INC. Fuzzy (name and state)
- Lobbying registrant: REGENXBIO Fuzzy (name and state)
- SEC filer: REGENXBIO Inc. EXACT (CIK (EXACT))
- Person page: David C Stump MD Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: James E Flynn Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther))
- Person page: Luke M Beshar Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-08-17 | S-1 | S-1 (registration) | REGENXBIO Inc. | 0001193125-15-292943 ↗ |
| 2015-09-08 | S-1/A | S-1/A (amendment) | REGENXBIO Inc. | 0001193125-15-313468 ↗ |
| 2015-09-15 | S-1/A | S-1/A (amendment) | REGENXBIO Inc. | 0001193125-15-320057 ↗ |
| 2015-09-16 | S-1/A | S-1/A (amendment) | REGENXBIO Inc. | 0001193125-15-320839 ↗ |
| 2015-09-16 | S-1MEF | S-1MEF (added securities) | REGENXBIO Inc. | 0001193125-15-321668 ↗ |
| 2015-09-16 | EFFECT | EFFECT (declared effective) | REGENXBIO Inc. | 9999999995-15-002524 ↗ |
| 2015-09-17 | 424B4 | 424B4 (final prospectus) | REGENXBIO Inc. | 0001193125-15-322464 ↗ |
| 2017-01-06 | EFFECT | EFFECT (declared effective) | REGENXBIO Inc. | 9999999995-17-000043 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-09-16 | S-1/A | registration statement | $22.00 | 5,555,555 | $122,222,210 | Nasdaq RGNX | 5 | primary document; price sentence, shares headline, proceeds computed, cover names 4 | document ↗ | |
| 2015-09-17 | 424B4 | final prospectus | $22.00 | 6,300,000 | $138,600,000 | Nasdaq RGNX | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BESHAR LUKE M | Director | 12 | 2015–2021 | person page Fuzzy | |
| DEERFIELD MANAGEMENT CO | TenPercentOwnerOther | 2 | 2015 | ||
| Deerfield Mgmt III, L.P. | TenPercentOwnerOther | 2 | 2015 | ||
| Deerfield Private Design Fund III, L.P. | TenPercentOwnerOther | 2 | 2015 | ||
| ENGLEMAN EDGAR | Director | 3 | 2015 | ||
| Flynn James E | TenPercentOwnerOther | 2 | 2015 | person page Fuzzy | |
| Fox Allan M. | Director; Director,TenPercentOwner | 17 | 2015–2026 | ||
| HAYDEN DONALD J JR | Director | 24 | 2015–2020 | ||
| KARABELAS ARGERIS N | Director | 19 | 2015–2026 | ||
| Mills Kenneth T. | Director; Director,Officer | President and CEO; See Remarks | 75 | 2015–2026 | |
| Samuels Camille D | Director | 3 | 2015–2016 | ||
| Simpson Curran | Director,Officer; Officer | Chief Executive Officer; Chief Oper. & Tech. Officer; See Remarks; SVP of Technical Operations; SVP, Product Development & CTO; SVP, Technical Operations | 40 | 2015–2026 | |
| Vasista Vittal | Officer | Chief Financial Officer; See Remarks | 59 | 2015–2024 | |
| Yoo Stephen | Officer | Chief Medical Officer | 14 | 2015–2018 | |
| Deerfield International Master Fund, L.P. | TenPercentOwnerOther | 1 | 2015 | ||
| Deerfield Mgmt L.P. | TenPercentOwnerOther | 1 | 2015 | ||
| DEERFIELD PARTNERS, LP | TenPercentOwnerOther | 1 | 2015 | ||
| FMR LLC | Other; TenPercentOwnerOther | 16 | 2015–2016 | ||
| STUMP DAVID C | Director | 13 | 2015–2026 | person page Fuzzy | |
| Ali Faraz | Officer | Chief Business Officer | 3 | 2016–2017 | |
| Abdun-Nabi Daniel | Director | 7 | 2016–2021 | ||
| Tasse Daniel | Director | 12 | 2016–2026 | ||
| Christmas Patrick J. | Officer | Chief Legal Officer; Chief Strategy & Legal Officer; Senior VP, General Counsel; SVP, General Counsel | 34 | 2016–2026 | |
| Danos Olivier | Officer | Chief Scientific Officer | 16 | 2017–2025 | |
| Glucksmann Alexandra | Director | 10 | 2018–2026 | ||
| PAKOLA STEVE | Officer | Chief Medical Officer | 19 | 2019–2026 | |
| Bennett Jean | Director | 7 | 2021–2026 | ||
| MIGAUSKY GEORGE V | Director | 7 | 2021–2026 | ||
| Zachary Jennifer | Director | 6 | 2022–2026 | ||
| Chan Mitchell | Officer | Chief Financial Officer | 6 | 2024–2026 | |
| Malzahn Craig | Officer | Chief Technology Officer | 5 | 2025–2026 | |
| Ciongoli Gregory Austin | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-05-28 | REGENXBIO Inc. | Biotechnology | $70,500,008 | $70,500,008 | 36 | 1 |
| 2015-01-23 | REGENXBIO Inc. | Biotechnology | $30,000,000 | $27,500,002 | 15 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | REGENXBIO Inc. | MD | State business registries | name and state |
| Business registration | REGENXBIO INC. | MD | State business registries | EIN (EXACT, as the state registration reports it) |
| Business registration | REGENXBIO INC. | MD | State business registries | name and state |
| Business registration | REGENXBIO INC. | MD | State business registries | name and state |
| Business registration | REGENXBIO INC. | MD | State business registries | name and state |
| Business registration | REGENXBIO INC. | MD | State business registries | name and state |
| Form D issuer | REGENXBIO Inc. | MD | Form D private offerings | CIK (EXACT) |
| Lobbying client | REGENXBIO | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | REGENXBIO | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | REGENXBIO | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | REGENXBIO INC. | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | REGENXBIO INC. | MD | Federal lobbying (LDA) | name and state |
| Lobbying registrant | REGENXBIO | MD | Federal lobbying (LDA) | name and state |
| Patent assignee | REGENXBIO INC. | MD | Patents (USPTO) | name and state |
| SEC filer | REGENXBIO Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | REGENXBIO Inc. | MD | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | REGENXBIO INC. | EIN (EXACT) | ||
| Person page | David C Stump MD | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | James E Flynn | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther) | |
| Person page | Luke M Beshar | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MD first:
- MICROMET, INC. MD
- OSIRIS THERAPEUTICS, INC. MD
- ELUTIA INC. MD
- CHAMPIONS ONCOLOGY, INC. MD
- CASI Pharmaceuticals, Inc (DE) MD
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
In other datasets, the same topic (Health) in MD:
- Nonprofit: 4K FOR CANCER INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health